Literature DB >> 20016020

Caspofungin-non-susceptible Candida isolates in cancer patients.

Diamantis P Kofteridis1, Russell E Lewis, Dimitrios P Kontoyiannis.   

Abstract

OBJECTIVES: To identify the frequency of caspofungin-non-susceptible Candida isolates in cancer patients with candidiasis.
METHODS: We reviewed the in vitro susceptibilities (M27-A3 CLSI method) of 650 Candida spp. associated with invasive candidiasis episodes in 582 hospitalized cancer patients (2005-08). RESULTS AND
CONCLUSIONS: We identified seven caspofungin-non-susceptible Candida strains (three Candida tropicalis, two Candida glabrata and two Candida albicans) from 650 Candida isolates (1%). C. tropicalis (three out of seven) was the most common non-susceptible species isolated. All patients responded to a change of antifungal therapy. Further surveillance should focus on the potential broader emergence of echinocandin resistance, as the clinical use of this antifungal class continues to expand in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20016020     DOI: 10.1093/jac/dkp444

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

2.  Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.

Authors:  Elodie Blanchard; Olivier Lortholary; Karine Boukris-Sitbon; Marie Desnos-Ollivier; Françoise Dromer; Didier Guillemot
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

3.  Pre-exposure of Candida species to cytarabine and daunorubicin does not affect their in vitro antifungal susceptibility and virulence in flies.

Authors:  Régis A Zanette; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2013-04-23       Impact factor: 5.882

Review 4.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

5.  Caspofungin resistant disseminated candidiasis in a 7-year-old girl with T cell lymphoma: a case report.

Authors:  Michael Schmalz; Manasa Joysula; Jack H Staddon; Arthur Feinberg
Journal:  Transl Pediatr       Date:  2018-01

6.  Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2010-12-08       Impact factor: 5.948

7.  Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.

Authors:  Alexander Lepak; Mariana Castanheira; Daniel Diekema; Michael Pfaller; David Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

8.  Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis.

Authors:  Ying-Lien Chen; Alexandra Brand; Emma L Morrison; Fitz Gerald S Silao; Ursela G Bigol; Fedelino F Malbas; Jeniel E Nett; David R Andes; Norma V Solis; Scott G Filler; Anna Averette; Joseph Heitman
Journal:  Eukaryot Cell       Date:  2011-04-29

9.  Isolation and identification of Candida species in patients with orogastric cancer: susceptibility to antifungal drugs, attributes of virulence in vitro and immune response phenotype.

Authors:  Lourimar Viana Nascimento F de Sousa; Vera Lúcia Santos; Andrea de Souza Monteiro; Marcus Vinicíus Dias-Souza; Sirlei Garcia Marques; Elaine Speziali de Faria; Elaine Alves de Oliveira Assunção; Simone Gonçalves Dos Santos; Juan Moises Zonis; Daniel Gomes de Alvarenga; Rodrigo Assunção de Holanda; Jaqueline Gontijo de Sousa; Kênia Valéria Dos Santos; Maria Aparecida de Resende Stoianoff
Journal:  BMC Infect Dis       Date:  2016-02-23       Impact factor: 3.090

10.  Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry.

Authors:  Narges Aslani; Ghasem Janbabaei; Mahdi Abastabar; Jacques F Meis; Mahasti Babaeian; Sadegh Khodavaisy; Teun Boekhout; Hamid Badali
Journal:  BMC Infect Dis       Date:  2018-01-08       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.